CliffBio
biologic

Cathflo Activase

alteplase

Loss of exclusivitySeptember 2013projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameCathflo Activase
Active ingredientalteplase
Strength2MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2001
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cathflo Activase patent cliff — loss of exclusivity September 2013 | CliffBio